Atara Biotherapeutics Operating Income Over Time
| ATRA Stock | USD 11.47 0.86 8.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Atara Biotherapeutics Performance and Atara Biotherapeutics Correlation. Atara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Atara Biotherapeutics and related stocks such as Fate Therapeutics, Sana Biotechnology, and Caribou Biosciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE | (13.3 M) | (13.3 M) | (13.6 M) | (17.7 M) | (24.9 M) | (27.8 M) | (32 M) | (42.1 M) | (67.1 M) | (100.7 M) | (128.1 M) | (217 M) | (308.4 M) | (190.5 M) | (181 M) |
| SANA | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (141.2 M) | (286.1 M) | (356.9 M) | (272.6 M) | (326.9 M) | (343.2 M) |
| CRBU | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (36.1 M) | (67 M) | (106.4 M) | (116.1 M) | (110.3 M) |
| RCUS | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (53.4 M) | (54.9 M) | (88.7 M) | (124.2 M) | 54.2 M | (280 M) | (340 M) | (323 M) |
| HRTX | (4.1 M) | (11.1 M) | (23.8 M) | (54.5 M) | (74.6 M) | (96.9 M) | (170.9 M) | (194.6 M) | (183.9 M) | (210.7 M) | (228.2 M) | (217.8 M) | (174.7 M) | (110.6 M) | (105.1 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (192.8 M) | (202 M) | (258.2 M) | (255.8 M) | (335.4 M) | (327.7 M) | (344.1 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (20 M) | (33.6 M) | (82.3 M) | (106.9 M) | (159.6 M) | (171.8 M) | (163.2 M) |
| KPTI | (10.3 M) | (10.3 M) | (15.9 M) | (34 M) | (75.8 M) | (119.1 M) | (110.7 M) | (130.5 M) | (179.9 M) | (189.3 M) | (171.8 M) | (98.3 M) | (142.2 M) | (129.5 M) | (136 M) |
| XFOR | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (24.3 M) | (36.1 M) | (45.9 M) | (51.7 M) | (59.9 M) | (85.1 M) | (87.6 M) | (107.5 M) | (102.1 M) |
| HOOK | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (21.2 M) | (51.1 M) | (53.3 M) | (81.7 M) | (73.2 M) | (97.7 M) | (92.8 M) |
| MREO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (36.2 M) | (45.3 M) | (35.2 M) | (39.5 M) | (37.6 M) | (20.9 M) | (43.6 M) | (28.4 M) | (29.8 M) |
| ABOS | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.9 M) | 61.6 M | (45.2 M) | (61.1 M) | (58.1 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (11.3 M) | (46.6 M) | (27.3 M) | (50.8 M) | (127.9 M) | (288 M) | (213.7 M) | (536.3 M) | (594.6 M) | (517.1 M) | (491.3 M) |
| ITOS | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (28 M) | (45.2 M) | 244.9 M | 126.3 M | (151.1 M) | (143.5 M) |
| TCRX | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (26.2 M) | (48.6 M) | (66.6 M) | (93.5 M) | (88.8 M) |
Atara Biotherapeutics and related stocks such as Fate Therapeutics, Sana Biotechnology, and Caribou Biosciences Operating Income description
Operating Income is the amount of profit realized from Atara Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Atara Biotherapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Atara Biotherapeutics | ATRA |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 11.47
Check out Atara Biotherapeutics Performance and Atara Biotherapeutics Correlation. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Atara Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.